Retatrutide (LY3437943) is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors. Its dose–response relationships with respect to side effects ...

Eli Lilly said its next-generation obesity drug retatutride cleared its first late-stage trial on Type 2 diabetes patients, helping them manage their blood sugar levels and lose weight. The drug ...

But while Ozempic is arguably the most recognizable drug in its class, it isn’t the only medication approved for weight management. Others include Wegovy and Saxenda, while newer drugs like ...

Please provide your email address to receive an email when new articles are posted on . Adults with obesity and knee osteoarthritis had reductions in body weight and knee pain with retatrutide. More ...

TRANSCEND-T2D-1 trial findings indicate that retatrutide provides significant improvements in HbA1c and cardiovascular risk factors. Topline results were announced from a phase 3 trial evaluating ...

You’ve heard of the popular glucagon-like peptide-1 (GLP-1) receptor agonist drug semaglutide (Ozempic, Wegovy) and GLP-1/GIP drug tirzepatide (Mounjaro, Zepbound). Now there’s a new kid on the weight ...

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or ...

Retatrutide is an new drug that has shown promise in the treatment of obesity and type 2 diabetes. Retatrutide is a type of multi-receptor agonist that targets multiple hormonal pathways involved in ...